Home・Elenco Azioni・Erasca Inc

Erasca Inc

Chiusa

15.8 -1.31

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

15.8

Massimo

16.17

Metriche Chiave
By Trading Economics
Entrata	139M -44M
EPS	-0.14
Dipendenti	103
EBITDA	139M -43M

Dividendi
By Acuity
Utili prossimi	10 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-627M 5.7B
Apertura precedente	17.11
Chiusura precedente	15.8

Erasca Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 set 2026, 23:51 UTC

China's House Price Index YoY release on September 15 expected to show continued decline amid cautious market sentiment and rising global oil prices.

12 set 2026, 23:41 UTC

Philadelphia Fed Manufacturing Index Set for Release Amid Heightened Market Sensitivity to Inflation and Interest Rate Hike Expectations.

12 set 2026, 23:41 UTC

U.S. Building Permits Expected to Reach 1.41 Million for August Amid Mixed Housing Sentiment Ahead of September Release

12 set 2026, 23:41 UTC

Housing Starts Data Release on September 17, 2026, Expected to Show Continued Caution Amid High Mortgage Rates and Recent Declines.

12 set 2026, 23:41 UTC

Upcoming U.S. Building Permits Report on September 17, 2026, Expected to Reflect Economic Health Amid Stable Market Sentiment.

12 set 2026, 23:41 UTC

Upcoming Housing Starts Data Release Amid Rising Mortgage Rates Raises Concerns for U.S. Construction Market

12 set 2026, 23:21 UTC

U.S. Retail Sales Ex Autos Expected to Rise 0.5% in August Amid Mixed Economic Sentiment and Inflation Concerns

12 set 2026, 23:21 UTC

U.S. Import Prices Expected to Rise 0.2% Amid Inflation Concerns and Fed Rate Speculation Following Geopolitical Tensions

12 set 2026, 23:21 UTC

U.S. Export Prices Expected to Rise in August Amid Positive Economic Sentiment and Fed Rate Speculations

12 set 2026, 23:21 UTC

U.S. Retail Sales Expected to Rise 0.9% in August Amid Cautious Market Sentiment Following July's Decline

12 set 2026, 23:11 UTC

Canada's housing starts data release on September 16, 2026, expected at 235,000 units amid cautious market sentiment following July’s shortfall.

12 set 2026, 23:01 UTC

NY Empire State Manufacturing Index Set for Release Amid Mixed Economic Sentiment and Inflation Concerns on September 15, 2026.

12 set 2026, 23:01 UTC

Market Awaits ECB President Lagarde's Speech Amid Speculation of Future Rate Hikes and Leadership Changes Following Recent Interest Rate Increase.

12 set 2026, 22:51 UTC

Brazil's Central Bank Set to Announce SELIC Rate Decision Amid Global Monetary Tightening and Rising Inflation Concerns on September 14, 2026.

12 set 2026, 22:51 UTC

Japan's Core Inflation Rate Expected to Rise to 1.8% Amid Global Economic Pressures Ahead of Bank of Japan Meeting

12 set 2026, 22:51 UTC

Japan's Upcoming Inflation Rate Report Expected to Reflect Mixed Signals Amid Rising Energy Costs and Producer Price Fluctuations

12 set 2026, 22:41 UTC

Canada's August Inflation Rate Release on September 14 Expected to Show Continued Pressure Amid Geopolitical Tensions and Rising Oil Prices.

12 set 2026, 22:41 UTC

Canada's Core Inflation Rate Expected to Rise to 2.4% Amid U.S. Economic Indicators and Speculation of Fed Interest Rate Hikes

12 set 2026, 22:41 UTC

Rising U.S. 30-Year Mortgage Rates Exceed 7%, Threatening Housing Demand and Economic Growth Ahead of Key Central Bank Meetings

12 set 2026, 22:41 UTC

Canada's Inflation Rate Expected to Hold Steady at 0.0% Amid Global Economic Concerns Ahead of September Release

12 set 2026, 22:41 UTC

Macro News

The DAX 30 Index is lower in after-market trading, pressured by rising crude oil prices and concerns over Treasury yields and interest rate hikes.

12 set 2026, 22:31 UTC

Japan's trade deficit forecasted at -1052.6 billion yen for August 2026 amid rising import costs and negative market sentiment.

12 set 2026, 22:31 UTC

Japan's August Exports YoY Data Set for Release Amidst Cautious Market Sentiment and Economic Concerns

12 set 2026, 22:31 UTC

Japan's Machinery Orders Expected to Decline Amid Market Volatility and Inflation Concerns

12 set 2026, 22:31 UTC

Brazil's Retail Sales Report on September 15 Expected to Show Month-on-Month Growth Amid Inflationary Pressures

12 set 2026, 22:11 UTC

Bank of England Expected to Maintain Interest Rate at 0.667% Amid Global Economic Caution and Inflation Concerns

12 set 2026, 21:01 UTC

Oil (Brent) is trading lower during after-market hours, continuing a decline since Friday's close. The market shows weakness despite remaining above its 20-day moving average.

12 set 2026, 21:01 UTC

India's August Inflation Rate Release on September 14 Expected at 4.8%, Amid Rising Global Energy Costs and Geopolitical Tensions

12 set 2026, 21:01 UTC

EUR/PLN traded roughly flat during after-market hours, remaining around the middle of its one-month range with no specific news identified.

12 set 2026, 20:51 UTC

API Crude Oil Stock Change Data Release on September 15 Expected to Show Continued Inventory Decline Amid Easing Geopolitical Tensions and Inflation Concerns.

Confronto tra pari

Modifica del prezzo

Erasca Inc Previsione

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Erasca Inc - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.